Overview
- Researchers led by W. David Arnold reported in the Journal of Clinical Investigation that communication between nerves and muscles becomes less reliable with age and contributes to sarcopenia.
- The team linked that failure to reduced levels of the NaV1.4 protein, which forms the sodium channels muscle fibers need to respond to nerve signals.
- In laboratory animals, partially blocking the muscle chloride channel ClC-1 restored nerve-to-muscle responsiveness and improved measured muscle strength, findings publicized in university releases on Sept. 24 and 25.
- Clinical precedent exists: ignaseclant, a ClC-1 partial inhibitor developed by NMD Pharma, produced functional gains in a multicenter trial of Charcot‑Marie‑Tooth disease and was presented by investigators at the 2026 MDA conference.
- The work sets a clear translational path from a lab discovery to human testing by proposing targeted clinical trials of ClC-1–directed drugs for older adults who have age-related weakness, a condition that affects nearly half of people over 80.